Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Bias remorse: are cancer drug trials clear enough on outcomes?
  2. Pharma Technology Focus: access to PrEP
  3. Data shows non-inferiority of SC administration of Roche’s Perjeta and Herceptin
  4. Janssen’s Darzalex outperforms standard of care in newly diagnosed multiple myeloma
  5. ViiV submits NDA for drug indicated for multi-drug resistant HIV

Latest Content

Bias remorse: are cancer drug trials clear enough on outcomes?

New analysis published in the British Medical Journal has found that almost half of pivotal trials forming the basis of EMA approvals of new cancer drugs were at high risk of bias based on their design, conduct or analysis. What exactly are the problems with cancer trial design and administration, and what needs to change? Study co-author Dr Huseyin Naci lends his insight.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top